ClinicalTrials.gg
RecruitingNCT05976516Updated Aug 4, 2023

CXCL2/CXCL8 Promote Intervertebral Disc Degeneration

An observational study in Cytokine and Intervertebral Disc, Degenerative, sponsored by Zhongda Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2023-08-04.

Sponsored by Zhongda Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 7 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Intervertebral Disc Degeneration with a site in China — 3 open to participants now, 3 under way, none of them phase 3. Intervertebral Disc Degeneration · China.

Started
2023
with 1 other
Observational
9 of 17
2 open now
Registered
14th of 17
by date

Among the 17 studies in Intervertebral Disc Degeneration with a site in China, this one is one of 2 that started in 2023, is one of 9 observational ones, and was the 14th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

3 of the 17 studies in Intervertebral Disc Degeneration with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Intervertebral Disc Degeneration with a site in China, or all of them as a file.
02

Study summary

Low back pain (LBP) is the largest cause of morbidity in the world, and about 80% of Chinese people are affected in their lifetime. Although the prevalence of IDD gradually increases with age, IDD is very common among subjects under 30 years old. In addition to age, there are other factors, such as excessive or uneven mechanical load, obesity, genetics, nutrition, trauma and gender. In addition, it is not clear whether the heavy physical load associated with occupation is an important risk factor for IDD. Some studies have found that IDD is more common among athletes than the general population. Due to the complexity and multifactorial nature of IDD, its pathogenesis and risk factors are still unclear, which seriously hinders the rational stratification of LBP patients and limits the development of personalized treatment.

03

Conditions studied

  • Cytokine
  • Intervertebral Disc, Degenerative

Keywords

  • cytokine
  • chemokine
  • Intervertebral Disc Degeneration
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with lumbar disc herniation who went to the spinal surgery department of Zhongda Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • It meets the diagnostic criteria of lumbar disc degeneration; No previous history of spinal surgery; Good ability of independent behavior and cooperation in completing research; The patient is aware of this study and has signed the consent form.

Exclusion criteria

Exclusion Criteria:

  • Patients with spinal tumor, infection, tuberculosis and other diseases; Patients with claustrophobia; Parkinson's syndrome patients; Poor cooperation, Poor image quality; Patients with osteoporosis.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • pirffmann 2 grade

    Diagnostic Test: CXCL2/CXCL8

  • pirffmann 3 grade

    Diagnostic Test: CXCL2/CXCL8

  • pirffmann 4 grade

    Diagnostic Test: CXCL2/CXCL8

  • pirffmann 5 grade

    Diagnostic Test: CXCL2/CXCL8

Interventions

  • Diagnostic testCXCL2/CXCL8

    Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group

06

What researchers measure

Primary outcomes

  1. CXCL2/8 content

    CXCL2/CXCL8 content of nucleus pulposus

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2023; primary completion for Mar 2024, 7 months later.

Of 80 observational studies under Intervertebral Disc Degeneration, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 84. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2023
First posted
Aug 4, 2023
StartEst.
Aug 1, 2023
Primary completionEst.
Mar 30, 2024
CompletionEst.
Mar 30, 2024
Last update
Aug 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05976516
Lead sponsor
Zhongda Hospital
Responsible party
pengfei, xue (Dr, Zhongda Hospital) — Principal investigator
First posted
Aug 4, 2023
Start date
Aug 1, 2023 (estimated)
Primary completion
Mar 30, 2024 (estimated)
Completion
Mar 30, 2024 (estimated)
Last update
Aug 4, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion